EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Vaxcell-Bio Therapeutics's enterprise value is ₩323,053.04 Mil.
Vaxcell-Bio Therapeutics's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was ₩26.64 Mil. Therefore, Vaxcell-Bio Therapeutics's EV-to-Revenue for today is 12,127.98.
The historical rank and industry rank for Vaxcell-Bio Therapeutics's EV-to-Revenue or its related term are showing as below:
XKRX:323990'
s EV-to-Revenue Range Over the Past 10 Years
Min: 11883.5 Med: 12966.77 Max: 16010.27
Current: 12127.98
During the past 5 years, the highest EV-to-Revenue of Vaxcell-Bio Therapeutics was 16010.27. The lowest was 11883.50. And the median was 12966.77.
XKRX:323990's EV-to-Revenue is ranked worse than 99.32% of 1033
companies
in the Biotechnology industry
Industry Median: 8.07
vs XKRX:323990: 12127.98
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Vaxcell-Bio Therapeutics's EV-to-Revenue
For the Biotechnology subindustry, Vaxcell-Bio Therapeutics's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vaxcell-Bio Therapeutics's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vaxcell-Bio Therapeutics's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Vaxcell-Bio Therapeutics's EV-to-Revenue falls into.
Vaxcell-Bio Therapeutics's current Enterprise Value is ₩323,053.04 Mil.
Vaxcell-Bio Therapeutics's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩26.64 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vaxcell-Bio Therapeutics's share price for today is ₩15990.00.
Vaxcell-Bio Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩1.16.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vaxcell-Bio Therapeutics EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Vaxcell-Bio Therapeutics's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Vaxcell-Bio Therapeutics (XKRX:323990) Business Description
Vaxcell-Bio Therapeutics is a bio-technology company engaged in the development of Cell-based and Protein-based Immunotherapeutics for the treatment of cancer.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
XKRX:323990 has been successfully added to your 